Compare CABA & RCKY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CABA | RCKY |
|---|---|---|
| Founded | 2017 | 1932 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Shoe Manufacturing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 319.6M | 273.7M |
| IPO Year | 2019 | 1996 |
| Metric | CABA | RCKY |
|---|---|---|
| Price | $3.67 | $39.23 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 1 |
| Target Price | $14.50 | ★ $40.00 |
| AVG Volume (30 Days) | ★ 5.1M | 55.7K |
| Earning Date | 05-14-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 1.71% |
| EPS Growth | 10.26 | ★ 94.74 |
| EPS | N/A | ★ 0.17 |
| Revenue | N/A | ★ $270,408,000.00 |
| Revenue This Year | N/A | $8.12 |
| Revenue Next Year | N/A | $4.90 |
| P/E Ratio | ★ N/A | $226.62 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.26 | $20.69 |
| 52 Week High | $4.23 | $48.70 |
| Indicator | CABA | RCKY |
|---|---|---|
| Relative Strength Index (RSI) | 55.61 | 57.18 |
| Support Level | $2.11 | $37.31 |
| Resistance Level | $3.73 | $44.83 |
| Average True Range (ATR) | 0.24 | 1.44 |
| MACD | 0.01 | 0.66 |
| Stochastic Oscillator | 61.41 | 93.28 |
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.
Rocky Brands Inc is a designer, manufacturer, and marketer of premium footwear and apparel under brands such as Muck, XTRATUF, Rocky, Durango, Georgia Boot, Lehigh, Ranger, and the licensed brand Michelin. The company operates through three segments, with the wholesale segment generating the majority of revenue through sales of footwear and accessories to sporting goods stores, outdoor specialty stores, online retailers, marine stores, independent retailers, mass merchants, retail uniform stores, and specialty safety shoe stores. The retail segment focuses on direct-to-consumer sales through e-commerce platforms and company-operated stores, while the contract manufacturing segment includes sales to the U.S. military, private label production, and sourcing arrangements for customers.